SEARCH

SEARCH BY CITATION

References

  • 1
    Mentlein R, Heymann E, Scholz W, Feller AC, Flad HD. Dipeptidyl peptidase IV as a new surface marker for a subpopulation of human T-lymphocytes. Cell Immunol. 1984; 89: 1119.
  • 2
    Yazbeck R, Sulda ML, Howarth GS et al. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis. 2010; 16: 13401351.
  • 3
    Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2009; 58: 641651.
  • 4
    Tian L, Gao J, Hao J et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology. 2010; 151: 30493060.
  • 5
    Masur K, Schwartz F, Entschladen F, Niggemann B, Zaenker KS. DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept. 2006; 137: 147155.
  • 6
    Boschmann M, Engeli S, Dobberstein K et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009; 94: 846852.
  • 7
    Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: Systematic review and meta-analysis. Adv Ther. 2012; 29: 1425.
  • 8
    Koren S, Shemesh-Bar L, Tirosh A et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 2012; 14: 561567.
  • 9
    Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13: 366373.
  • 10
    Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011; 58: 6973.
  • 11
    Ogawa S, Ishiki M, Nako K et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011; 223: 133135.
  • 12
    Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368: 16961705.
  • 13
    Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010; 3: 195201.
  • 14
    Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012; 23: 565570.
  • 15
    Chen L, Klein T, Leung PS. Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice. Curr Mol Med. 2012; 12: 9951004.
  • 16
    Shirakawa J, Fujii H, Ohnuma K et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011; 60: 12461257.
  • 17
    Ferreira L, Teixeira-de-Lemos E, Pinto F et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010; 2010: 592760.
  • 18
    Shah Z, Kampfrath T, Deiuliis JA et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011; 124: 23382349.
  • 19
    Dobrian AD, Ma Q, Lindsay JW et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab. 2011; 300: E410421.
  • 20
    Bekur R, Nagaraja MV, Shivashankara KN, Stanley W. Sitagliptin-induced hemolysis. Indian J Pharmacol. 2010; 42: 320321.
  • 21
    Pitocco D, Zaccardi F, Martini F et al. Severe leucopenia associated with sitagliptin use. Diabetes Res Clin Pract. 2011; 91: e3032.
  • 22
    Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: An increased risk of angioedema. Hypertension. 2009; 54: 468470.
  • 23
    Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009; 54: 516523.
  • 24
    Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012; 35: e60.
  • 25
    Yokota K, Igaki N. Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: A case report. Intern Med. 2012; 51: 20412044.
  • 26
    Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 1993; 261: 466469.
  • 27
    Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998; 161: 5570.
  • 28
    Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci. 2009; 30: 600607.
  • 29
    Reinhold D, Bank U, Buhling F et al. Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology. 1997; 91: 354360.
  • 30
    Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985; 312: 14051411.
  • 31
    Hildebrandt M, Rose M, Ruter J, Salama A, Monnikes H, Klapp BF. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol. 2001; 36: 10671072.
  • 32
    Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Clin Chem. 1989; 35: 10161018.
  • 33
    Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004; 305: 10001003.
  • 34
    Korom S, De Meester I, Stadlbauer TH et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 1997; 63: 14951500.
  • 35
    Matteucci E, Ghimenti M, Di Beo S, Giampietro O. Altered proportions of naive, central memory and terminally differentiated central memory subsets among CD4+ and CD8 + T cells expressing CD26 in patients with type 1 diabetes. J Clin Immunol. 2011; 31: 977984.
  • 36
    Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: A pilot, double-blind, randomized, crossover trial. Diabet Med. 2011; 28: 11761181.
  • 37
    Suarez-Pinzon WL, Cembrowski GS, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia. 2009; 52: 16801682.
  • 38
    Suarez-Pinzon WL, Rabinovitch A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces beta-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice. Cell Transplant. 2011; 20: 13431349.
  • 39
    Liang J, Leung KK, Lam SY, Leung PS. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells. Diabetes Obes Metab. 2012; 14: 842851.
  • 40
    Pospisilik JA, Martin J, Doty T et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003; 52: 741750.
  • 41
    Stecca BA, Nardo B, Chieco P, Mazziotti A, Bolondi L, Cavallari A. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J Hepatol. 1997; 27: 337345.
  • 42
    Inamoto T, Yamochi T, Ohnuma K et al. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix. Clin Cancer Res. 2006; 12: 34703477.
  • 43
    Inamoto T, Yamada T, Ohnuma K et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res. 2007; 13: 41914200.
  • 44
    Stremenova J, Krepela E, Mares V et al. Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int J Oncol. 2007; 31: 785792.
  • 45
    Bauvois B, De Meester I, Dumont J, Rouillard D, Zhao HX, Bosmans E. Constitutive expression of CD26/dipeptidyl peptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br J Cancer. 1999; 79: 10421048.
  • 46
    Carbone A, Gloghini A, Zagonel V et al. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood. 1995; 86: 46174626.
  • 47
    Gonzalez-Gronow M, Kaczowka S, Gawdi G, Pizzo SV. Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Front Biosci. 2008; 13: 16101618.
  • 48
    Munoz E, Blazquez MV, Madueno JA, Rubio G, Pena J. CD26 induces T-cell proliferation by tyrosine protein phosphorylation. Immunology. 1992; 77: 4350.
  • 49
    Sato T, Yamochi T, Aytac U et al. CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res. 2005; 65: 69506956.
  • 50
    Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 2005; 65: 13251334.
  • 51
    Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer. 2004; 109: 855866.
  • 52
    Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S. Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. 2002; 62: 27532757.
  • 53
    Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med. 1999; 190: 311322.
  • 54
    Hartmann B, Harr MB, Jeppesen PB et al. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab. 2000; 85: 28842888.
  • 55
    Drucker DJ, Shi Q, Crivici A et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol. 1997; 15: 673677.
  • 56
    Jeppesen PB, Hartmann B, Thulesen J et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001; 120: 806815.
  • 57
    Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept. 2005; 124: 105112.
  • 58
    Korner M, Rehmann R, Reubi JC. GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn's disease. Mol Cell Endocrinol. 2012; 364: 4653.
  • 59
    Thulesen J, Hartmann B, Hare KJ et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut. 2004; 53: 11451150.
  • 60
    Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013; 15: 112120.
  • 61
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580591.
  • 62
    Bartness TJ, Song CK. Thematic review series: Adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. J Lipid Res. 2007; 48: 16551672.
  • 63
    Rosmaninho-Salgado J, Marques AP, Estrada M et al. Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-gamma expression. Peptides. 2012; 37: 4954.
  • 64
    Briand F, Thieblemont Q, Burcelin R, Sulpice T. Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes Obes Metab. 2012; 14: 662665.
  • 65
    Pacheco BP, Crajoinas RO, Couto GK et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens. 2011; 29: 520528.
  • 66
    Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010; 56: 728733.
  • 67
    Mistry GC, Maes AL, Lasseter KC et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008; 48: 592598.
  • 68
    Liu L, Liu J, Wong WT et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012; 60: 833841.
  • 69
    Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension. 2008; 51: 16371642.
  • 70
    Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23: 168175.
  • 71
    Kroller-Schon S, Knorr M, Hausding M et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res. 2012; 96: 140149.
  • 72
    Matsubara J, Sugiyama S, Sugamura K et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012; 59: 265276.
  • 73
    Nikolaidis LA, Elahi D, Hentosz T et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004; 110: 955961.
  • 74
    Ossum A, van Deurs U, Engstrom T, Jensen JS, Treiman M. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9–36)a in an isolated rat heart. Pharmacol Res. 2009; 60: 411417.
  • 75
    Lim S, Choi SH, Shin H et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS ONE. 2012; 7: e35007.
  • 76
    Nikolaidis LA, Mankad S, Sokos GG et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004; 109: 962965.
  • 77
    Gomez N, Touihri K, Matheeussen V et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012; 14: 1421.
  • 78
    Beijers HJ, Ferreira I, Spronk HM et al. Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: Potential role of central adiposity and low-grade inflammation: The Hoorn Study. Thromb Res. 2012; 129: 557562.
  • 79
    Loeffen R, Spronk HM, ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost. 2012; 10: 12071216.
  • 80
    Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: Role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012; 35: 20762082.
  • 81
    Makdissi A, Ghanim H, Vora M et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab. 2012; 97: 33333341.
  • 82
    Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care. 2010; 33: 23492354.
  • 83
    Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298: 194206.
  • 84
    Willemen MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: A disproportionality analysis in the World Health Organization VigiBase. Diabetes Care. 2011; 34: 369374.
  • 85
    Grouzmann E, Monod M, Landis B et al. Loss of dipeptidyl peptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J. 2002; 16: 11321134.
  • 86
    Klemann C, Schade J, Pabst R et al. CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently. Clin Exp Immunol. 2009; 155: 357365.
  • 87
    Lankas GR, Leiting B, Roy RS et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005; 54: 29882994.
  • 88
    Ospelt C, Mertens JC, Jungel A et al. Inhibition of fibroblast activation protein and dipeptidyl peptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2010; 62: 12241235.
  • 89
    Toyoda-Akui M, Yokomori H, Kaneko F et al. A case of drug-induced hepatic injury associated with sitagliptin. Intern Med. 2011; 50: 10151020.